<?xml version="1.0" encoding="UTF-8"?>
<ref id="B51-antibiotics-10-00024">
 <label>51.</label>
 <element-citation publication-type="journal">
  <person-group person-group-type="author">
   <name>
    <surname>Almeida-Souza</surname>
    <given-names>F.</given-names>
   </name>
   <name>
    <surname>Silva</surname>
    <given-names>V.D.D.</given-names>
   </name>
   <name>
    <surname>Silva</surname>
    <given-names>G.X.</given-names>
   </name>
   <name>
    <surname>Taniwaki</surname>
    <given-names>N.N.</given-names>
   </name>
   <name>
    <surname>Hardoim</surname>
    <given-names>D.J.</given-names>
   </name>
   <name>
    <surname>Buarque</surname>
    <given-names>C.D.</given-names>
   </name>
   <name>
    <surname>Abreu-Silva</surname>
    <given-names>A.L.</given-names>
   </name>
   <name>
    <surname>Calabrese</surname>
    <given-names>K.D.S.</given-names>
   </name>
  </person-group>
  <article-title>1,4-Disubstituted-1,2,3-Triazole compounds induce ultrastructural alterations in leishmania amazonensis promastigote: An in vitro antileishmanial and in silico pharmacokinetic study</article-title>
  <source>Int. J. Mol. Sci.</source>
  <year>2020</year>
  <volume>21</volume>
  <elocation-id>6839</elocation-id>
  <pub-id pub-id-type="doi">10.3390/ijms21186839</pub-id>
 </element-citation>
</ref>
